Pacific Biosciences of California Inc [NASDAQ: PACB] slipped around 9169998.71 points on Monday, while shares priced at $9170000.0 at the close of the session, down -3.88%.
Pacific Biosciences of California Inc stock is now -8.49% down from its year-to-date (YTD) trading value. PACB Stock saw the intraday high of $1.33 and lowest of $1.225 per share. The company’s 52-week high price is 2.72, which means current price is +45.88% above from all time high which was touched on 01/08/25.
Compared to the average trading volume of 9.17M shares, PACB reached a trading volume of 11659392 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Pacific Biosciences of California Inc [PACB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $1.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.21. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Pacific Biosciences of California Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 11, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on June 03, 2024, representing the official price target for Pacific Biosciences of California Inc stock. On April 18, 2024, analysts decreased their price target for PACB shares from 7 to 2.50.
The Price to Book ratio for the last quarter was 4.06, with the Price to Cash per share for the same quarter was set at 1.15.
How has PACB stock performed recently?
Pacific Biosciences of California Inc [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.20. With this latest performance, PACB shares gained by 19.23% in over the last four-week period, additionally sinking by -36.41% over the last 6 months – not to mention a drop of -32.24% in the past year of trading.
Pacific Biosciences of California Inc [PACB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc [PACB] shares currently have an operating margin of -401.03% and a Gross Margin at -230.61%. Pacific Biosciences of California Inc’s Net Margin is presently recorded at -430.93%.
Return on Equity for this stock declined to -51.89%, with Return on Assets sitting at -51.89%.
Earnings analysis for Pacific Biosciences of California Inc [PACB]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc go to 27.35%.
Insider trade positions for Pacific Biosciences of California Inc [PACB]
There are presently around $66.11%, or 72.70% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 33.21 million shares, which is approximately 12.1932%. VANGUARD GROUP INC, holding 26.0 million shares of the stock with an approximate value of $$35.62 million in PACB stocks shares; and VANGUARD GROUP INC, currently with $$32.34 million in PACB stock with ownership which is approximately 8.6674%.
